MOTS-c, GHK-Cu, & KPV Blend

MOTS-c, GHK-Cu & KPV Blend has no established direct evidence for the exact combination. Component evidence is scientifically interesting but should be presented conservatively. MOTS-c is a mitochondrial-derived peptide studied in metabolic and muscle-homeostasis models; mouse studies report effects on obesity, insulin resistance, metabolites, and age-related physical decline, while human data are mainly observational or exercise-associated rather than drug-exposure trials. GHK-Cu has wound-repair and connective-tissue research, including topical diabetic-ulcer evidence and rat wound studies. KPV has anti-inflammatory evidence in cell and murine colitis models. These component findings do not show that combining MOTS-c, GHK-Cu, and KPV is beneficial, safe, synergistic, or appropriate for human use.

MOTS-c Metabolic Models

MOTS-c promoted metabolic homeostasis and reduced obesity and insulin resistance in mouse models, and was reported as an exercise-induced mitochondrial-encoded regulator of age-related physical decline ^[1][2].

GHK-Cu and KPV Component Evidence

GHK-Cu has topical diabetic-ulcer and preclinical connective-tissue evidence, while KPV reduced inflammatory signaling and mouse colitis severity in preclinical studies ^[3][4].

Direct Blend Gap

No source evaluated the exact MOTS-c, GHK-Cu, and KPV blend.

FDA Human-Exposure Gaps

FDA states it has not identified human exposure data for MOTS-c or KPV drug products by any route, and notes injectable GHK-Cu immunogenicity and impurity concerns ^[5].

Translation Limitation

MOTS-c and KPV evidence cited here is primarily preclinical, while GHK-Cu human evidence is topical and not equivalent to systemic use ^[1][3][4].